EP. 1: Renal Cell Carcinoma and Novel Therapies
As the biology of renal cell carcinoma becomes better understood, so does the management of the disease, including the use of novel therapies.
EP. 2: Supportive Care and Systemic Therapy for RCC
Advice to health care providers on when to refer patients for further assessment of potential renal cell carcinoma and insight on the types of diagnostic tests used to help confirm a diagnosis in the era of molecular testing.
EP. 3: Newly Diagnosed RCC: Treatment Planning
Guidelines and recommendations by clinicians on treatment approaches for newly diagnosed renal cell carcinoma and regimens in the pipeline that may impact future treatment.
EP. 4: Risk Stratification in Renal Cell Carcinoma
A historical overview regarding the development of parameters used to help stratify risk in patients with renal cell carcinoma and the relevance of current models in the context of selecting systemic therapy to treat appropriate patients.
EP. 5: mRCC Risk Assessment and Treatment Options
Preferred treatment regimens that incorporate novel therapies used to treat patients with metastatic renal cell carcinoma based on risk status.
EP. 6: Treatment Planning and Risk Assessment in mRCC
The importance of risk assessment when selecting frontline therapy to treat advanced renal cell carcinoma and factors to consider when talking with patients about goals of therapy.
EP. 7: Supportive Care for mRCC: Current Practices
Drs Robert Alter and Robert Motzer discuss the rationale and use of surgery as supportive care to treat appropriate patients with metastatic renal cell carcinoma.
EP. 10: Second-Line Treatment Approaches for mRCC
Oncologists discuss their preferences in regard to second-line therapy for metastatic renal cell carcinoma, and optimal timing for changing regimens based on responses to treatment.
Robert Motzer, MD, describes what lenvatinib is and explains the rationale for studying its use in combination with novel therapies such as everolimus as treatment for metastatic renal cell carcinoma.
EP. 12: Lenvatinib Combination Data in mRCC
Robert Alter, MD, highlights various trial data on the management of advanced renal cell carcinoma with the combination of lenvatinib and everolimus, also commenting on the potential outcomes associated with the use of lenvatinib with pembrolizumab.
EP. 13: Current RCC Treatment Limitations
Health care experts remark on current unmet needs associated with the use of novel therapies, such as immunotherapies, and targeted treatments for metastatic renal cell carcinoma and share advice on best practices when managing patients in the community.